Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and Hypercholesterolaemia: A preliminary report

Current Vascular Pharmacology

Volumn 12, Issue 3, 2014, Pages 505-511

  Kargiotis, Konstantinos ^a   Katsiki, Niki ^a   Athyros, Vasilios G ^a   Giouleme, Olga ^a   Patsiaoura, Kalliopi ^b   Katsiki, Evangelia ^b   Mikhailidis, Dimitri P ^c   Karagiannis, Asterios ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b Aristotle University of Thessaloniki   (Greece)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Dyslipidaemia; Metabolic syndrome; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Rosuvastatin

Indexed keywords

FENOFIBRATE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG DOSE TITRATION; DYSLIPIDEMIA; ECHOGRAPHY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIVER BIOPSY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OPEN STUDY; PROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 84910010800     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990009     Document Type: Article

References (44)

1. [1] Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
2. [2] McCullough AJ. Pathophysiology of non-alcoholic steatohepatitis. J Clin Gastroenterol 2006; 40(Suppl 1): S17-29.
3. [3] Lonardo A, Sookoian S, Chonchol M, Loria P, Targher G. Cardio- vascular and Systemic Risk in Nonalcoholic Fatty Liver Disease-Atherosclerosis As a Major Player in the Natural Course of NAFLD. Curr Pharm Des 2013; 19(29): 5177-92.
4. [4] Athyros VG, Katsiki N, Karagiannis A. Nonalcoholic Fatty Liver Disease and Severity of Cardiovascular Disease Manifestations. Angiology 2013; 64(8): 572-5.
5. [5] Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-49.
6. [6] Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79-104.
7. [7] Tziomalos K, Athyros VG, Karagiannis A. Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. Curr Vasc Pharmacol 2012; 10: 162-72.
8. [8] Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Current treatment for nonalcoholic fatty liver disease. Expert Opin Pharma- cother 2011; 12: 2141-2.
9. [9] Bader T. Liver tests are irrelevant when prescribing statins. Lancet 2010; 376: 1882-3.
10. [10] Bader T. Yes! Statins can be given to liver patients. J Hepatol 2012; 56: 305-7.
11. [11] Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, Pagourelias ED, Theocharidou E, Karagiannis A, Mikhailidis DP; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-22.
12. [12] Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011; 7: 796-805.
13. [13] Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial. J Hepatol 2012; 57: 476.
14. [14] Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multi- factorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006; 22: 873-83.
15. [15] Liberopoulos EN, Athyros VG, Elisaf MS, Mikhailidis DP. Statins for non-alcoholic fatty liver disease: a new indication? Aliment Pharmacol Ther 2006; 24: 698-9.
16. [16] Athyros VG, Tziomalos K, Daskalopoulos GN, Karagiannis A, Mikhailidis DP. Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med 2011; 43: 167-71.
17. [17] Hyogo H, Tazuma S, Arihiro K, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57: 1711-8.
18. [18] Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004; 174: 193-6.
19. [19] Hyogo H, Ikegami T, Tokushige K, et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipide- mia: An open-label, pilot study. Hepatol Res 2011; 41: 1057-65.
20. [20] Nakahara T, Hyogo H, Kimura Y, et al. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res 2012; 42: 1065-72.
21. [21] Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009; 49: 80-86.
22. [22] Valenzuela R, Videla L. The importance of the long-chain polyun- saturated fatty acid n-6/n-3 ratio in development of non-alcoholic fatty liver associated with obesity. Food Funct 2011; 2: 644-8.
23. [23] Agouridis AP, Tsimihodimos V, Filippatos TD, Tselepis AD, Elisaf MS. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. Lipids 2011; 46: 521-8.
24. [24] Bonnet J, McPherson R, Tedgui A, et al. CAP Investigators. Com- parative effects of 10-mg versus 80-mg Atorvastatin on high- sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther 2008; 30: 2298-313.
25. [25] Ghaisas MM, Dandawate PR, Zawar SA, Ahire YS, Gandhi SP. Antioxidant, antinociceptive and anti-inflammatory activities of atorvastatin and rosuvastatin in various experimental models. Inflammopharmacology 2010; 18: 169-77.
26. [26] Nam HK, Lee SJ, Kim MH, et al. Rosuvastatin attenuates inflam- mation, apoptosis and fibrosis in a rat model of cyclosporine- induced nephropathy. Am J Nephrol 2013; 37: 7-15.
27. [27] Okada Y, Yamaguchi K, Nakajima T, et al. Rosuvastatin amelio- rates high-fat and high-cholesterol diet-induced nonalcoholic stea- tohepatitis in rats. Liver Int 2013; 33: 301-11.
28. [28] Gianella A, Nobili E, Abbate M, et al. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke- prone rats. Am J Pathol 2007; 170: 1165-77.
29. [29] Mayer C, Gruber HJ, Landl EM, et al. Rosuvastatin reduces inter- leukin-6-induced expression of C-reactive protein in human hepa- tocytes in a STAT3- and C/EBP-dependent fashion. Int J Clin Pharmacol Ther 2007; 45: 319-27.
30. [30] Malaguarnera M, Vacante M, Russo C, et al. Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with -interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patients. Hepat Mon 2011; 11: 92-8.
31. [31] Maffioli P, Fogari E, D'Angelo A, Perrone T, Derosa G. Ultrasono- graphy modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvas- tatin in type 2 diabetic patients not well controlled by metformin. Eur J Gastroenterol Hepatol 2013; 25(9): 1113-22.
32. [32] Fraulob JC, Souza-Mello V, Aguila MB, Mandarim-de-Lacerda CA. Beneficial effects of rosuvastatin on insulin resistance, adipos- ity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet. Clin Sci (Lond) 2012; 123: 259-70.
33. [33] Kiyici M, Gulten M, Gurel S, et al. Ursodeoxycholic acid and atorvastatin in the treatment of non-alcoholic steatohepatitis. Can J Gastroenterol 2003; 17: 713-8.
34. [34] Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007; 47: 135-41.
35. [35] Andersson CX, Gustafson B, Hammarstedt A, Hedjazifar S, Smith U. Inflamed adipose tissue, insulin resistance and vascular injury. Diabetes Metab Res Rev 2008; 24: 595-603.
36. [36] Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
37. [37] Mizrahi M, Shabat Y, Ben Ya'acov A, et al. Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH. J Inflamm Res 2012; 5: 141-50.
38. [38] Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009; 106: 15430-5.
39. [39] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and man- agement of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, Ameri- can College of Gastroenterology, and the American Gastroen- terological Association. Hepatology 2012; 55: 2005-23.
40. [40] Rizzo M, Montalto G, Vinciguerra M. Exploring lipid-related treatment options for the treatment of NASH. Curr Vasc Pharmacol 2012.
41. [41] Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, Gandhi P. Meta-analysis of drug-induced adverse events associ- ated with intensive-dose statin therapy. Clin Ther 2007; 29: 253-60.
42. [42] Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cho- lesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survi- vors of myocardial infarction: a double-blind randomised trial. Lancet 2010; 376: 1658-69.
43. [43] Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental De- crease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437-45.
44. [44] Kasliwal R, Wilton LV, Cornelius V, Aurich-Barrera B, Shakir SA. Safety profile of rosuvastatin: results of a prescription-event moni- toring study of 11,680 patients. Drug Saf 2007; 30: 157-70.